PROPHYLACTIC MIGRAINE MEDICATION USE IN PRIMARY CARE SETTING IN FINLAND

Author(s)

Wahlman H1, Purmonen T1, Korolainen M1, Forsström J2
1Novartis Finland Oy, Espoo, Finland, 2Multirec Oy, Turku, Finland

OBJECTIVES:

Migraine is a disabling health condition. While it is the most common among working-aged people, it presents significant indirect costs on society, especially when the attacks are frequent. It is important to define the current treatment when new therapies are entering the market. Aim of this study was to assess the use of prophylactic treatments in a primary care setting in Finland.

METHODS:

We conducted a retrospective register-based study on prescription data from primary healthcare electronic medical records. This register covers an overall primary health care patient population of 2,1 million, which includes almost 40 % of the Finnish population. For this study, prophylactic treatments were extracted from the data (1.1.2014- 31.1.2018) and only newly initiated prophylactic treatments were taken into account. To be included in the new user cohort, 24 months period without any medication on migraine was required prior to identification of 1st prophylactic treatment. When assessing the treatment lines, a new prescription indicated the start of a new treatment. Minimum 13 months follow-up time was required.

RESULTS:

Altogether 2095 patients starting new prophylactic treatment were identified. Regardless the treatment line, the most commonly used prophylactic drugs were bisoprolol (22,9 %), candesartan (20,5 %), amitriptyline (18,7 %), propranolol (11,8 %), metoprolol (11,7 %), topiramate (4,3 %), nortriptyline (2,2 %) and amitriptyline+antipsyphotic (2,1 %). Bisoprolol (n=512; 24,4%), Candesartan (n=422; 20,1 %) and amitriptylin (n=370; 17,7 %) were the most commonly used prophylactic treatments in first-line. Only a small proportion of patients, who received prophylactic treatment, initiated second-line treatment (n=182; 8,7 %) or third-line treatment n=21; 1,0 %) .

CONCLUSIONS:

Variety different of substances are used for migraine prophylaxis in primary care in Finland. First-line prophylactic migraine treatments are regularly used, but the second-line or third-line treatments are initiated infrequently.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PND85

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Prescribing Behavior, Treatment Patterns and Guidelines

Disease

Neurological Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×